| KKR & CO INC. |
| USA |
| Finanzen |
| US48251W1045 / A2LQV6 |
| KR51 (Frankfurt) / KKR (NYSE) |
| FRA:KR51, ETR:KR51, KR51:GR, NYSE:KKR |
| - |
| https://www.kkr.com/ |
|
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases. The company’s programs are designed to make precise changes at the RNA level, aiming to address dis..
>Volltext.. |
| 69987.33 Mio. EUR |
| 145093.08 Mio. EUR |
| 20937.19 Mio. EUR |
| 5026.17 Mio. EUR |
| 2804.46 Mio. EUR |
| 2.98 EUR |
| 49089.34 Mio. EUR |
| 18864.59 Mio. EUR |
| 8209.05 Mio. EUR |
| 1.44 |
| 35.98% |
| 58.57% |
| 0.65 EUR |
| 0.87% |
| 0.89% |
| 10.08.26 - 0.1688895€ 15.05.26 - 0.167661€ >weitere anzeigen... |
| - |
| KKR & CO, KOHLBERG KRAVIS, KKR |
| 20.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|